Neoplasms, Nerve Tissue  >>  mipsagargin (G-202)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
mipsagargin (G-202) / Rebus
NCT02067156: Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma

Completed
2
26
US
G-202, Mipsagargin
GenSpera, Inc., Food and Drug Administration (FDA)
Glioblastoma Multiforme
12/16
02/17

Download Options